BIONTECH 2024 Q3
Earnings Overview & AI Insights

Earnings Performance

Michael?ur?ahin -- Co-Founder and Chief Executive Officer -- is at the forefront of the company's oncology pipeline. We made significant achievements during the third quarter, including advancements across our pipeline and a strong start to the new season. Biotech was looking to revolutionize cancer treatment to the development of mRNA-based immunotherapies particularly to personalized cancervaccines. The company has launched a new Phase II clinical trial with Genentech in bladder cancer patients. BNT327, our bispecific antibody targeting PD-L1 and VGFA has emerged as a key molecule in our pipeline. Ugur Tureci -- Co-Founder and Chief Medical Officer -- will discuss progress on BNP327 and our efforts on our therapeutic mRNA cancer vaccine fund. Ugur: "We entered a truly exciting period for BioNTech and progress toward our founding vision" Influenza and SARS-CoV-2 and influenza show different patterns of seasonality. The emergence of new variants, coupled with a weighing of both vaccine and infection induced in immunocompromised individuals indicates the susceptibility to COVID-19 infection remains a concern after the winter vaccine season. BNT327 is a bispecific antibody candidate that targets both PD-L1 and VGFA that's combined two combined two complementary functions. The binding of BNT 327 is designed to deliver superior anti-tumor compared to individual individual targets. BMT327 in combination with nab-paclitaxel has shown a high objective response rate with long progression-free survival. The drug class at large is showing a single validated mechanism of action, where doseoptimization price in the U.S. has been initiated recently initiated recently. BNT327 combination in standard of care chemotherapies is an intended path to market approach. Biotheus and BMS' mRNA cancer vaccine platform, iNeST target neoantigens necrosometic mutations in cancer cells that are unique to the individual tumor. For BNT113, our mRNA vaccine candidate against HPV16-positive cancer, we presented data from two trials at ESMO conference. BNT111 includes fourmelanoma associated antigens, which collectively cover more than 90% of melanoma patients and are highly immunogenic. The FixVac data updates provided in Q3 are a proof of concept in three dimensions. BNT111 a lower oil combination with anti-PD-1-compound induced high magnitude T-cell responses against at least one targeted tumor related antigen in all analyzed patients, most of which were notdetected prior to using the vaccine. The results we saw in the Phase II study are consistent with results seen in the previous study. The five-year survival rate in PDAC after PDAC is 10%. Up to 75% of patients with PDACrelapse even though they appear tumor free within five years after treatment. Adjuvant treatment of master mastermastermaster-invasive urothelial carcinoma is an important opportunity to avoid recurrent metastases. Revenues for the third quarter of 2024 were approximately EUR  EUR 1.245 billion. The increase compared to the same period last year can be largely attributed to early approvals of our variant adapted COVID-19 vaccines this year. We expect to report a loss for the 2024 financial year of 2024 as we continue to invest in our pipeline. We are committed to responsible and sustainable growth. We have lowered our SG&A expenses and capital expenditures guidance. We will continue to monitor the risk of potential write-downs to determine the full scope of charges related to the 2024 vaccination season. The company is focused on investing in innovative technologies that we believe can have the greatest impact on medical practice while progressing late-stage programs toward potential approvals. We continue to execute on our successful launch of this season's JN1 and KP.2 variant adaptive vaccines in more than 40 countries and regions. South Korea, Singapore and Brazil. The epidemiology of COVID-19 over the last two years and the associated global demand for vaccination continue to support our view that the global vaccine market for the foreseeable future. We expect to maintain or even gain market share in a number of key markets this year. We're entering a catalyst-rich period for our company, in particular, for our oncology portfolio.